PatrickDriscoll

I serve the interests of medical technology company decision-makers, venture-capitalists, and others with interests in medtech producing worldwide analyses of medical technology markets for my audience of mostly medical technology companies (but also rapidly growing audience of biotech, VC, and other healthcare decision-makers). I have a small staff and go to my industry insiders (or find new ones as needed) to produce detailed, reality-grounded analyses of current and potential markets and opportunities. I am principally interested in those core clinical applications served by medical devices, which are expanding to include biomaterials, drug-device hybrids and other non-device technologies either competing head-on with devices or being integrated with devices in product development. The effort and pain of making every analysis global in scope is rewarded by my audience's loyalty, since in the vast majority of cases they too have global scope in their businesses.Specialties: Business analysis through syndicated reports, and select custom engagements, on medical technology applications and markets in general/abdominal/thoracic surgery, interventional cardiology, cardiothoracic surgery, patient monitoring/management, wound management, cell therapy, tissue engineering, gene therapy, nanotechnology, and others.
Follow:
183 Articles

Global Trend in Bariatric Surgery

The global obesity problem has been targeted by multiple alternative therapies including…

PatrickDriscoll PatrickDriscoll

Regulation of Wound Management Products

The passage below is from the MedMarket Diligence Report #S247, “Worldwide Wound…

PatrickDriscoll PatrickDriscoll

Tissue Engineering and Cell Therapy to Grow to Over $30 Billion Global Market

The market for tissue engineering and cell therapy products is set to…

PatrickDriscoll PatrickDriscoll

Medtech Startups, November 2011

Below is a list of the companies identified in November 2011 and…

PatrickDriscoll PatrickDriscoll

Growth and Uptake of Ablation Technologies in Clinical Practice

Technologies for the therapeutic ablation of tissues are diverse — from ultrasound…

PatrickDriscoll PatrickDriscoll

Changing Fortunes in the Obesity Treatment Industry

With Qnexa, Contrave and Lorcaserin each recently rejuvenated after previous FDA's near-death…

PatrickDriscoll PatrickDriscoll

Ablation Technologies in Liver Cancer

Radio frequency ablation (RFA), with limitations, has shown to be effective and…

PatrickDriscoll PatrickDriscoll

European Obesity Drug and Device Markets

Arguably, the biggest threat in the field of healthcare is the looming…

PatrickDriscoll PatrickDriscoll

Changing Dynamics of Medtech Investing

It has been recently postulated and debated whether there has lately been…

PatrickDriscoll PatrickDriscoll

FDA Accepts NDA for VIVUS’ Qnexa

VIVUS, Inc., has announced that the FDA has accepted its new drug…

PatrickDriscoll PatrickDriscoll